国药现代发布2025年度权益分派实施公告，现金分红细节披露
上海现代制药股份有限公司（证券代码：600420，简称“国药现代”）于2026年5月26日发布了2025年度权益分派实施公告，详细披露了本次利润分配方案的具体内容及相关实施细则。此次公告内容对投资者具有重要参考价值，特别是涉及现金分红、税收政策及发放时间表等关键事项，可能对公司股价产生潜在影响。
一、分红方案要点
- 每股分红比例： A股每股现金红利0.20元（含税）。
- 分红总额： 本次利润分配以总股本1,341,172,692股为基数，共计派发现金红利268,234,538.40元。
- 差异化分红送转： 无差异化分红送转。
二、重要日期
| 股份类别 | 股权登记日 | 除权（息）日 | 现金红利发放日 |
|---|---|---|---|
| A股 | 2026/6/2 | 2026/6/3 | 2026/6/3 |
投资者需特别关注股权登记日（2026年6月2日）及除权除息日（2026年6月3日），以确保享有本次分红权益。
三、分红对象及实施细则
- 分红对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司登记在册的所有股东。
- 红利发放方式： 无限售条件流通股的红利将通过中国结算上海分公司资金清算系统发放。已办理指定交易的投资者可在指定证券营业部领取红利，未办理指定交易的则暂由中国结算上海分公司保管，待办理指定交易后再发放。
- 部分大股东红利发放： 对于中国医药集团有限公司、上海医药工业研究院有限公司、中国医药投资有限公司、国药集团一致药业股份有限公司和国药控股股份有限公司，公司将直接发放红利。
四、税收政策及实际到手分红
- 个人投资者及证券投资基金：
- 持股期限超1年，红利免征个人所得税，实际派发0.20元/股。
- 持股期限1年以内，暂不扣税，实际派发0.20元/股，转让时由券商代扣代缴。
- QFII（合格境外机构投资者）： 统一代扣10%企业所得税，税后每股0.18元。如需享受税收协定待遇，可自行向税务机关申请。
- 沪港通投资者（企业及个人）： 由公司通过中国结算上海分公司按股票名义持有人（香港中央结算有限公司）账户以人民币派发，按10%税率代扣代缴，税后每股0.18元。
- 其他机构投资者及法人股东： 公司不代扣企业所得税，由纳税人自行申报，实际派发0.20元/股。
五、投资者须知及潜在价格影响因素
- 分红比例及持续现金回报彰显公司稳健经营： 此次较高分红比例（0.20元/股，合计2.68亿元）显示公司现金流充裕，有助于增强投资者信心，可能对股价形成正面支撑。
- 分红税收政策及实际到手收益需关注： 投资者应根据自身持股期限及身份（个人、机构、QFII、港股通）核算实际到手红利，避免税务风险。
- 重要日期影响交易安排： 股权登记日与除权除息日临近，短线投资者需注意分红前后的交易安排，规避因除权导致的价格波动。
- 大股东直接分红安排无特殊变化： 公司对主要控股股东分红直接发放，有助于简化流程，不影响中小投资者权益。
六、联系方式
联系地址： 上海市浦东新区建陆路378号
部门： 董事会办公室
电话： 021-52372865
免责声明： 本文内容仅供投资参考，不构成任何投资建议。投资有风险，入市需谨慎。具体分红及税收事项请以公司公告和相关法规为准，投资者如有疑问请咨询专业人士或公司董秘部门。
Shanghai Modern Pharmaceutical (Sinopharm Modern) Announces 2025 Dividend Distribution Plan—Investors to Receive CNY 0.20 per Share
Shanghai Modern Pharmaceutical Co., Ltd. (Stock Code: 600420, “Sinopharm Modern”) released its 2025 annual dividend implementation announcement on May 26, 2026. The notice details the cash dividend plan, key dates, tax policies, and other procedures that are highly relevant for shareholders and may influence share price.
Key Points of the Dividend Plan
- Per Share Dividend: CNY 0.20 (before tax) per A-share.
- Total Dividend: Based on a total share capital of 1,341,172,692 shares, the company will distribute CNY 268,234,538.40 in cash dividends.
- No differentiated dividend or share bonus arrangement.
Important Dates
| Share Class | Record Date | Ex-Dividend Date | Dividend Payment Date |
|---|---|---|---|
| A-share | 2026/6/2 | 2026/6/3 | 2026/6/3 |
Investors must pay attention to the record date (June 2, 2026) and ex-dividend date (June 3, 2026) to ensure eligibility for this round of dividends.
Dividend Recipients and Implementation Details
- Recipients: All shareholders registered at China Securities Depository and Clearing Corporation’s Shanghai branch by the close of trade on the record date.
- Distribution Method: Dividends for unrestricted shares will be distributed via the clearing system. Those with specified brokerage accounts will receive dividends in their accounts; those without will have dividends held until account specification is completed.
- Direct Payment to Major Shareholders: Dividends to major shareholders (including China National Pharmaceutical Group, Shanghai Institute of Pharmaceutical Industry, and others) will be paid directly by the company.
Tax Policy and After-tax Dividend Details
- Individual Investors & Public Funds:
- Holding over 1 year: No individual income tax, receive CNY 0.20/share.
- Holding within 1 year: No tax withheld at distribution, but tax will be withheld upon share transfer.
- QFII (Qualified Foreign Institutional Investors): 10% withholding tax applied; after-tax dividend is CNY 0.18/share. QFIIs can apply for treaty benefits if eligible.
- Hong Kong Stock Connect Investors: 10% withholding tax; after-tax dividend is CNY 0.18/share.
- Other Institutional and Corporate Investors: No withholding; investors must self-report and pay taxes, receive CNY 0.20/share.
Investor Reminders and Potential Price Drivers
- Robust Dividend Payout Shows Company’s Strength: The dividend ratio (CNY 0.20/share; total payout CNY 268 million) underscores strong cash flows, which may positively affect market confidence and share price.
- Tax Policy May Impact Net Receipts: Investors should calculate post-tax dividend based on their holding period and investor type to avoid surprises.
- Key Dates Could Impact Trading: Shareholders should plan ahead for the record and ex-dividend dates, as price adjustments typically occur on the ex-dividend date.
- No Special Arrangements for Major Shareholders: Direct payments to major holders streamline operations but do not affect minority shareholders’ rights.
Contact Information
Address: 378 Jianlu Road, Pudong New Area, Shanghai
Department: Board Secretary Office
Phone: 021-52372865
Disclaimer: The above content is for informational purposes only and does not constitute investment advice. Please refer to official company disclosures and consult your financial advisor for specific guidance. Investing involves risks; please proceed with caution.
